Fox Run Management L.L.C. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Fox Run Management L.L.C. boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 262.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,264 shares of the biotechnology company’s stock after purchasing an additional 7,434 shares during the quarter. Fox Run Management L.L.C.’s holdings in Blueprint Medicines were worth $895,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of Blueprint Medicines during the third quarter worth approximately $32,000. R Squared Ltd acquired a new position in Blueprint Medicines during the 4th quarter worth approximately $51,000. Asset Management One Co. Ltd. purchased a new stake in shares of Blueprint Medicines in the 4th quarter valued at approximately $88,000. Van ECK Associates Corp increased its position in shares of Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 363 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $108,000.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the transaction, the insider now owns 14,967 shares of the company’s stock, valued at $1,496,700. This represents a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,334 shares of company stock worth $3,103,512 over the last ninety days. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Trading Up 0.3 %

NASDAQ:BPMC opened at $88.72 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The stock’s 50 day simple moving average is $99.47 and its 200-day simple moving average is $93.88. Blueprint Medicines Co. has a 12-month low of $80.68 and a 12-month high of $121.90. The firm has a market cap of $5.67 billion, a P/E ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BPMC. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They set an “outperform” rating for the company. Morgan Stanley started coverage on Blueprint Medicines in a research report on Thursday. They set an “equal weight” rating and a $100.00 price objective for the company. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Stephens reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.